Details of Disease

General Information of Disease (ID: DISW6UF1)

Disease Name Autoimmune diabetes
Synonyms diabetes mellitus, congenital autoimmune
Disease Class 5A10: Diabetes mellitus
Disease Hierarchy
DISYKSRF: Genetic disease
DISW6UF1: Autoimmune diabetes
ICD Code
ICD-11
ICD-11: 5A10
Disease Identifiers
MONDO ID
MONDO_0011507
MESH ID
C565730
UMLS CUI
C1857958
OMIM ID
605026
MedGen ID
347586

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 6 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Etrasimod DMT0A3Y Approved NA [1]
Galavit DMUS4B2 Approved NA [2]
Immunosuppressant synthetic peptide DMFKB34 Approved NA [3]
N-Acetyl-D-glucosamine DM1XBWR Approved Small molecular drug [4]
WinRho SDF DMXANR0 Approved NA [2]
Anti-MIF antibodies DM8EKSV Phase 4 NA [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 59 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anti-CD3 monoclonal antibody DMQ0DAU Phase 3 NA [6]
AT1001 DMRV4DT Phase 3 Small molecular drug [7]
DiaPep-277 DM4XBM7 Phase 3 Small molecular drug [8]
SAND-26 DMKHLRT Phase 3 Antibody [9]
Triptolide DMCMDVR Phase 3 Small molecular drug [10]
YourDex DMWIBVI Phase 3 NA [11]
MOR-208 DMDQOWT Phase 2/3 Antibody [12]
ALX-0061 DMO1VHC Phase 2 Antibody [13]
BCX-3408 DMRSG31 Phase 2 Small molecular drug [14]
CCX-354 DMSHV9C Phase 2 NA [15]
DM199 DM0157T Phase 2 Recombinant protein [16]
Estetrol DMTB63Q Phase 2 Small molecular drug [17]
FP-187 DMWZO21 Phase 2 NA [18]
IMO-3100 DMM549D Phase 2 NA [19]
MCS-18 DMX4U0B Phase 2 NA [20]
MIS-416 DM7K4YR Phase 2 NA [21]
MM-093 DMXJWNS Phase 2 NA [22]
NI-0501 DMGUHYW Phase 2 NA [23]
NI-0801 DMRQUH4 Phase 2 Antibody [24]
OvaSave DMRZKKC Phase 2 NA [25]
PG-102 DMF5YEN Phase 2 NA [26]
Phenylalanine hydroxylase DMRP3CV Phase 2 NA [27]
Rocilinostat DMSTH01 Phase 2 Small molecular drug [28]
Semapimod DMIJNLG Phase 2 Small molecular drug [29]
TNF alpha kinoid DM3AIF7 Phase 2 Vaccine [30]
Xmab 5871 DMLIPY1 Phase 2 NA [31]
ApoCell DMEA3ZA Phase 1/2 NA [32]
FPA-008 DM3ZN6Y Phase 1/2 NA [33]
NI-0401 DMEOLVP Phase 1/2 Antibody [34]
XToll DM148HX Phase 1/2 NA [35]
AMG 357 DM3ORVG Phase 1 NA [36]
AMP-110 DM6V4I3 Phase 1 NA [37]
ARGX-110 DMYG23I Phase 1 NA [38]
BT-063 DMS4H30 Phase 1 Antibody [39]
Cx-621 DMJLNBT Phase 1 NA [40]
ELND-002 DMM9S51 Phase 1 NA [41]
ELND-004 DMLQYVD Phase 1 NA [42]
HMPL-011 DMZCXMA Phase 1 NA [43]
Humanized SMART Anti-IL-12 Antibody DMMH15S Phase 1 NA [44]
MAXY-4 DMMP7XG Phase 1 NA [45]
MB-11040 DMLKJKR Phase 1 NA [46]
MCAF5352A DMSMQU1 Phase 1 NA [47]
MDX-018 DML5FX2 Phase 1 NA [48]
MORAb-022 DMM7TBO Phase 1 Antibody [49]
MTRX-1011A DMEKUNO Phase 1 NA [50]
NI-0101 DM31FOP Phase 1 Antibody [51]
NI-0701 DM32VKQ Phase 1 NA [52]
NN-8828 DMYXDB9 Phase 1 Antibody [53]
PI-0824 DMMLWH5 Phase 1 NA [54]
PLX-5622 DMK4PWM Phase 1 NA [55]
PPI-2458 DMSAQBC Phase 1 Small molecular drug [56]
REV-576 DMLHIMO Phase 1 NA [57]
RO-5310074 DMG14MT Phase 1 NA [58]
SGN-70 DMXA7W9 Phase 1 Antibody [59]
TRX-1 DMD16KW Phase 1 NA [60]
TT-30 DMLDSX8 Phase 1 NA [61]
UR-13870 DM7YTTS Phase 1 NA [62]
VBY- 891 DMTKPH4 Phase 1 NA [63]
VBY-129 DM4YIWK Phase 1 NA [64]
------------------------------------------------------------------------------------
⏷ Show the Full List of 59 Drug(s)
This Disease is Treated as An Indication in 20 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CVT-124 DM753RT Discontinued in Phase 3 Small molecular drug [65]
HBP-347 DMX3IRE Discontinued in Phase 3 NA [66]
Tresperimus DMOVBSF Discontinued in Phase 3 Small molecular drug [67]
MDX-214 DMXB20Y Discontinued in Phase 1/2 Antibody [68]
TGN-1412 DMELNA8 Discontinued in Phase 1 Antibody [69]
B-220 DM6920K Terminated Small molecular drug [71]
CDP-855 DMDIZDK Terminated NA [72]
CGP-47969A DMGD31P Terminated NA [73]
Genimune DMX8Y02 Terminated NA [74]
HuMax-TAC DM8BSF3 Terminated Antibody [75]
LCP-3301 DM1NGI0 Terminated NA [76]
LX-2932 DMMRLPF Terminated Small molecular drug [77]
LZ-8 DM679IY Terminated NA [78]
Maxy-10 DM31WQC Terminated NA [79]
Org-4094 DMC8DHX Terminated Small molecular drug [80]
Ruthenium complexes DMJ9UQT Terminated NA [81]
SC-114 DMHDKA6 Terminated NA [82]
SKF-105685 DMN9Y9K Terminated Small molecular drug [83]
SKF-106610 DMEPDTE Terminated Small molecular drug [84]
TSK-204 DMISW55 Terminated NA [85]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
PCI-45292 DMW3TGI Preclinical NA [70]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 104 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
2-Bromopalmitate DMM6UGE Investigative Small molecular drug [86]
2LM20-4 DMZD348 Investigative NA [87]
99mTc-ImmuRAID-LL1 DMTJNRO Investigative NA [86]
AC-710 DMXS72J Investigative Small molecular drug [88]
AD-412 DMJMCDP Investigative NA [89]
AFC-5128 DM65TUP Investigative NA [90]
AFM-15 DMXO8GY Investigative NA [86]
AM-3840 DM2AOF8 Investigative NA [91]
Amooranin DMC15DM Investigative NA [92]
ANA-04 DMIY134 Investigative Antibody [93]
Anti-GM-CSF human mabs DMA1JV7 Investigative Monoclonal antibody [86]
Anti-IFN-alpha human mabs DM8IDUM Investigative Monoclonal antibody [86]
Anti-TLR3 mabs DMN76A4 Investigative Monoclonal antibody [94]
Anti-TNF human mabs DMYKTF6 Investigative Antibody [95]
AP-501 DMRILW7 Investigative NA [86]
APG-2305 DMBSDTR Investigative NA [96]
Aponidin DMKWSTY Investigative NA [86]
ARGX-109 DMDK9RY Investigative NA [86]
AT-002 DMAE05B Investigative NA [86]
AT-007 DMB00F8 Investigative NA [86]
AT-008 DMODLPS Investigative NA [97]
Atrimer DMC1M4U Investigative NA [86]
B7/CD28 costimulatory proteins DMH0G5M Investigative NA [86]
BTma22 DM5RRND Investigative NA [86]
CAB-101 DMYDFQ7 Investigative NA [86]
CD200Fc DM64KJ0 Investigative NA [86]
CGEN-15001 DMQOSXO Investigative NA [86]
CGEN-25007 DM3VOTR Investigative NA [86]
CGI-1316 DMTPRBX Investigative Small molecular drug [98]
CRB-15 DMNCUVI Investigative NA [86]
CT-637 DMEHKG5 Investigative NA [86]
Cx-911 DM1J4DG Investigative NA [86]
DARPins DML302L Investigative NA [86]
DD-3 DMRUTCU Investigative NA [86]
Debio-1036 DMZ49MP Investigative NA [86]
DNX-2000 DMC5RL7 Investigative NA [99]
DP-5599 DM3F5CZ Investigative NA [86]
FM-501 DMB2ONF Investigative NA [86]
FP-1069 DMJ382F Investigative NA [86]
FP-289 DMA76O9 Investigative NA [86]
FR-104 DM7UP4E Investigative Antibody [100]
GL-2045 DMWG1ME Investigative Small molecular drug [86]
GT-1282 DMNMITH Investigative Small molecular drug [86]
GX-C4 DM8GFJP Investigative Antibody [101]
HC3-1496 DM1BLCX Investigative NA [102]
ICT-69 DMWLQQO Investigative NA [86]
IdeS DMKA53D Investigative NA [86]
IMP-731 DM1TQXO Investigative NA [103]
IPH-24 DMWFYZJ Investigative NA [86]
IS-0402 DMFE86U Investigative NA [86]
ISU-201 DMUMDAZ Investigative NA [86]
JNJ-10329670 DMBRJ3C Investigative Small molecular drug [91]
KANAb-071 DMH2KS3 Investigative NA [86]
KLS-40 DMBFR4B Investigative NA [86]
KRP-107 DM5KFBP Investigative NA [104]
KX-03 DM7QANY Investigative NA [86]
L-790070 DMJKAQR Investigative Small molecular drug [105]
Leukotoxin DMYX2NJ Investigative Small molecular drug [106]
LP-0067 DMWTJ3E Investigative NA [107]
M-3000 DM6YBH3 Investigative Small molecular drug [86]
MAT-303 DM6NIZT Investigative NA [86]
MAT-304 DMEO24N Investigative NA [86]
MDT-012 DMQKGC2 Investigative NA [86]
MEDI-553 DM960DQ Investigative Antibody [108]
MKC-204 DMQOKSV Investigative NA [86]
MM-POD1 DMADXY8 Investigative NA [86]
MN-8001 DMQU179 Investigative NA [86]
MP-0210 DMSNM2T Investigative NA [86]
MP-0270 DMIBH15 Investigative NA [86]
Nextomabs DMWHLOK Investigative Monoclonal antibody [86]
NI-1201 DM680XO Investigative Antibody [109]
NI-1401 DMG9OBA Investigative Antibody [93]
NSD-726 DMJH434 Investigative NA [86]
NZ-39000 DMHXKZL Investigative NA [86]
ONX-0914 DMYUQJ8 Investigative Small molecular drug [86]
PA-517 DMKEHRT Investigative NA [86]
Peniel-5000 DMV9PMG Investigative NA [86]
PG-120 DMWP0BX Investigative Antibody [110]
PMA-101R DM7XURA Investigative NA [86]
PMA-201 DM4MAE5 Investigative NA [86]
PMA-411R DMQUQT9 Investigative NA [86]
PMA-511R DM2GQRR Investigative NA [86]
PRS-190 DM08X7E Investigative NA [86]
PT DM3AL1O Investigative Small molecular drug [86]
REC-200 DM21Q5P Investigative NA [86]
Recruitin DMEFYYA Investigative NA [86]
SEL-113 DMJC6GZ Investigative NA [86]
SFc DMLW3SC Investigative Small molecular drug [86]
SIVIG DMXH9LS Investigative NA [86]
Soluble CD83 DMS9S9I Investigative NA [86]
Stapled peptides DMYP5JC Investigative NA [86]
TMX-201 DMULO0V Investigative Vaccine [111]
TMX-30X DMSEAMU Investigative NA [111]
Toleragens DMCG3PF Investigative NA [86]
TRX-385 DM1BS6R Investigative NA [86]
TTI-314 DMTXPNU Investigative NA [86]
VLST-002 DMUUEJN Investigative NA [86]
VT-362 DMG1Q0W Investigative NA [112]
VTX-763 DMGTB95 Investigative NA [113]
WilGraf DMHQKLJ Investigative NA [86]
WSB-102 DME2XEP Investigative NA [86]
WSB-290 DM84NZL Investigative NA [86]
WSB-961 DMP85LK Investigative NA [86]
WSBI-19711A DM7W8D3 Investigative NA [86]
------------------------------------------------------------------------------------
⏷ Show the Full List of 104 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 ClinicalTrials.gov (NCT02447302) Safety and Efficacy of APD334 in Patients With Ulcerative Colitis. U.S. National Institutes of Health.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Dipeptide gamma-d-Glu-d-Trp (thymodepressin) inhibits migration of CD34+ cells from the bone marrow into peripheral blood during tumor growth. Bull Exp Biol Med. 2008 Jul;146(1):96-9.
4 Drug information of N-Acetyl-D-glucosamine, 2008. eduDrugs.
5 ClinicalTrials.gov (NCT01452997) Evaluation of Anti-inflammatories in the Reduction of Bite Reactions. U.S. National Institutes of Health.
6 EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop. Expert Rev Clin Immunol. 2013 Feb;9(2):95-7.
7 ClinicalTrials.gov (NCT00925301) Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT01460251) OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277. U.S. National Institutes of Health.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8691).
10 ClinicalTrials.gov (NCT02115659) Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). U.S. National Institutes of Health.
11 ClinicalTrials.gov (NCT00481312) Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU). U.S. National Institutes of Health.
12 ClinicalTrials.gov (NCT01685008) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin Lymphoma (NHL). U.S. National Institutes of Health.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363).
14 ClinicalTrials.gov (NCT01407874) A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT01242917) A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy. U.S. National Institutes of Health.
16 ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health.
17 ClinicalTrials.gov (NCT00563472) Feasibility Study Into the Contraceptive Effect of Estetrol. U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT01230138) Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
19 Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
20 The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
21 Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014.
22 ClinicalTrials.gov (NCT00458146) A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT01818492) A Study to Investigate the Safety and Efficacy of an Anti-IFN mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis. U.S. National Institutes of Health.
24 ClinicalTrials.gov (NCT01430429) Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody. U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT02327221) Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT01106703) The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels. U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT00925054) Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU. U.S. National Institutes of Health.
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7010).
29 ClinicalTrials.gov (NCT00038766) CNI-1493 for Treatment of Moderate to Severe Crohn's Disease. U.S. National Institutes of Health.
30 ClinicalTrials.gov (NCT01911234) Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis. U.S. National Institutes of Health.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125)
32 ClinicalTrials.gov (NCT00524784) Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD. U.S. National Institutes of Health.
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039179)
34 ClinicalTrials.gov (NCT00805909) NI-0401 in Patients With Acute Renal Allograft Rejection. U.S. National Institutes of Health.
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024733)
36 ClinicalTrials.gov (NCT01695876) A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT01878123) Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT01813539) Phase 1b Study of ARGX-110 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023007)
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035385)
41 ClinicalTrials.gov (NCT01318421) A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis. U.S. National Institutes of Health.
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024932)
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031183)
44 Protein Design Labs Announces Development of SMART(TM) Anti-IL-12 Antibody. Protein Design Labs, Inc. MAY 02, 2001.
45 ClinicalTrials.gov (NCT02052375) A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With RheumatoidArthritis on Methotrexate. U.S. National Institutes of Health.
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035049)
47 ClinicalTrials.gov (NCT01540760) A Study of MCAF5352A in Healthy Volunteers. U.S. National Institutes of Health.
48 Clinical pipeline report, company report or official report of Genmab.
49 ClinicalTrials.gov (NCT01357759) Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects. U.S. National Institutes of Health.
50 ClinicalTrials.gov (NCT00718588) A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis. U.S. National Institutes of Health.
51 ClinicalTrials.gov (NCT01808469) First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers. U.S. National Institutes of Health.
52 ClinicalTrials.gov (NCT01255501) First in Human Study of NI-0701 in Healthy Volunteers. U.S. National Institutes of Health.
53 ClinicalTrials.gov (NCT01208506) First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
54 ClinicalTrials.gov (NCT00063752) Safety Study of PI-0824 to Treat Pemphigus Vulgaris. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT01282684) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers. U.S. National Institutes of Health.
56 ClinicalTrials.gov (NCT00100347) Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors. U.S. National Institutes of Health.
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042907)
58 ClinicalTrials.gov (NCT01199809) A Study of RO5310074 in Patients With Psoriatic Arthritis. U.S. National Institutes of Health.
59 2011 Pipeline of Seattle Genetics.
60 A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14.
61 ClinicalTrials.gov (NCT01335165) Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH). U.S. National Institutes of Health.
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016928)
63 ClinicalTrials.gov (NCT01947738) Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1). U.S. National Institutes of Health.
64 Clinical pipeline report, company report or official report of ViroBay.
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015498)
66 Heat shock protein 90 (Hsp90). SciBX 4(18).
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004804)
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019614)
69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020365)
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029717)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021876)
72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008925)
73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004375)
74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007336)
75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018175)
76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029455)
77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021957)
78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006001)
79 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016147)
80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003322)
81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010794)
82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005485)
83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001545)
84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001930)
85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013403)
86 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
87 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
88 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8095).
89 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
92 Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
93 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).
94 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753).
95 Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
96 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
97 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
98 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8066).
99 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
100 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).
101 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
102 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842).
103 IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
104 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
105 Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of ... J Med Chem. 2008 Jul 24;51(14):4122-49.
106 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2451).
107 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
108 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2786).
109 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
110 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
111 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
112 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1877).
113 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758).